Association of serum steroid levels with survival in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel on ECOG-ACRIN E3805.

被引：0
|
作者：
Mostaghel, Elahe A.
Wang, Xin Victoria
Marck, Brett
Matsumoto, Alvin M.
Sweeney, Christopher
机构：
[1] VA Puget Sound Hlth Care Syst, Seattle, WA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
146
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Re: Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
    Sweeney, C. J.
    Martin, A. J.
    Stockler, M. R.
    Begbie, S.
    Chi, K. N.
    Chowdhury, S.
    Coskinas, X.
    Frydenberg, M.
    Hague, W. E.
    Horvath, L. G.
    Joshua, A. M.
    Lawrence, N. J.
    Marx, G. M.
    McCaffrey, J.
    McDermott, R.
    McJannett, M.
    North, S. A.
    Parnis, F.
    Parulekar, W.
    Pook, D. W.
    Reaume, M. N.
    Sandhu, S. K.
    Tan, A.
    Tan, T. H.
    Thomson, A.
    Tu, E.
    Vera-Badillo, F.
    Williams, S. G.
    Yip, S.
    Zhang, A. Y.
    Zielinski, R. R.
    Davis, I. D.
    JOURNAL OF UROLOGY, 2021, 206 (06): : 1519 - 1520
  • [32] Seven- Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel
    Harshman, Lauren C.
    Chen, Yu-Hui
    Liu, Glenn
    Carducci, Michael A.
    Jarrard, David
    Dreicer, Robert
    Hahn, Noah
    Garcia, Jorge A.
    Hussain, Maha
    Shevrin, Daniel
    Eisenberger, Mario
    Kohli, Manish
    Plimack, Elizabeth R.
    Cooney, Matthew
    Vogelzang, Nicholas J.
    Picus, Joel
    Dipaola, Robert
    Sweeney, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04) : 376 - +
  • [33] Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805)
    Harshman, Lauren C.
    Wang, Victoria X.
    Hamid, Anis A.
    Santone, Gabriella
    Drake, Charles G.
    Carducci, Michael A.
    DiPaola, Robert S.
    Fichorova, Raina N.
    Sweeney, Christopher J.
    PROSTATE, 2020, 80 (16): : 1429 - 1437
  • [34] Underutilization of androgen deprivation therapy (ADT) intensification for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC): A systematic review of real-world database studies.
    Raval, Amit D.
    Chen, Stephanie
    Littleton, Natasha
    Constantinovici, Niculae
    Goebell, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 66 - 66
  • [35] Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study
    Kalebasty, Arash Rezazadeh
    Hammerer, Peter
    Tombal, Bertrand
    Hussain, Maha
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, David
    Zhang, Weijiang
    Ploeger, Bart
    Li, Rui
    Kuss, Iris
    Zieschang, Carsten
    Wittemer-Rump, Sabine
    Smith, Mathew
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 80 - 81
  • [36] Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
    Kyriakopoulos, Christos E.
    Chen, Yu-Hui
    Carducci, Michael A.
    Liu, Glenn
    Jarrard, David F.
    Hahn, Noah M.
    Shevrin, Daniel H.
    Dreicer, Robert
    Hussain, Maha
    Eisenberger, Mario
    Kohli, Manish
    Plimack, Elizabeth R.
    Vogelzang, Nicholas J.
    Picus, Joel
    Cooney, Matthew M.
    Garcia, Jorge A.
    DiPaola, Robert S.
    Sweeney, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (11) : 1080 - +
  • [37] Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study.
    Rezazadeh, Arash
    Tombal, Bertrand F.
    Hussain, Maha H. A.
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Kapur, Shivani
    Zhang, Weijiang
    Ploeger, Bart
    Li, Rui
    Kuss, Iris
    Zieschang, Carsten
    Wittemer-Rump, Sabine
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [38] Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809)
    McNeel, Douglas G.
    Chen, Yu-Hui
    Gulley, James L.
    Dwyer, Alexander J.
    Madan, Ravi A.
    Carducci, Michael A.
    DiPaola, Robert S.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (10) : 2469 - 2474
  • [39] Baseline bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer (mHSPC): Patient-level analysis of SWOG 1216 trial.
    Gebrael, Georges
    Jo, Yeonjung
    Swami, Umang
    Plets, Melissa
    Chehade, Chadi Hage
    Narang, Arshit
    Gupta, Shilpa
    Myint, Zin
    Sayegh, Nicolas
    Tangen, Catherine
    Hussain, Maha H. A.
    Dorff, Tanya B.
    Lara, Primo N.
    Lerner, Seth P.
    Thompson, Ian M.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 188 - 188
  • [40] Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial.
    Saad, Fred
    Hussain, Maha H. A.
    Tombal, Bertrand F.
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Thiele, Silke
    Li, Rui
    Kuss, Iris
    Joensuu, Heikki
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345